Dextran-based prodrug-nanoassemblies responsively releasing pidotimod and camptothecin for anti-breast cancer
The dextran-based pH/GSH-responsive prodrug-nanoassemblies with synergistic therapy efficacy and low systemic toxicity may offer a novel strategy for breast cancer therapy.
Authors
- Bingfeng Zhang (ORCID: https://orcid.org/0000-0001-5751-2873)
- Jiamin Li (ORCID: https://orcid.org/0000-0002-6443-1710)
- Jiajun Cui (ORCID: https://orcid.org/0000-0002-9000-371X)
- Pengfei Gao (ORCID: https://orcid.org/0000-0001-6909-4701)
Institutions
- Yichun University (CN)
Publication Details
- Journal
- Drug Development and Industrial Pharmacy
- Published
- 2025-06-09
- DOI
- https://doi.org/10.1080/03639045.2025.2517726
- Citations
- 2
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 1.59